Código QR (código de barras bidimensional)

Novel therapies are changing treatment paradigms in metastatic prostate cancer

Abstract Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA dama...

ver descrição completa

Na minha lista:
Principais autores: Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, Tian Zhang
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2020-10-01
coleção:Journal of Hematology & Oncology
Assuntos:
Metastatic prostate cancer
Castration-resistant prostate cancer
Prostate-specific membrane antigen (PSMA)
Polyadenosine diphosphate [ADP]-ribose polymerase (PARP) inhibitor
Androgen receptor inhibitors (ARIs)
Acesso em linha:http://link.springer.com/article/10.1186/s13045-020-00978-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados